Rolando Iglesias
Internal Medicine · Coral Gables, FLNPI 1730199092
Payments from drug & device makers
Across 168 payments — averaging $20.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$595
- Boehringer Ingelheim$497
- Sumitomo Pharma America, Inc.$411
- Novartis$304
- Johnson & Johnson$238
- Lilly USA, LLC$228
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,522100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $595 |
| Boehringer Ingelheim | 24 | $497 |
| Sumitomo Pharma America, Inc. | 17 | $411 |
| Novartis | 16 | $304 |
| Johnson & Johnson | 12 | $238 |
| Lilly USA, LLC | 12 | $228 |
| AstraZeneca | 6 | $225 |
| Sunovion Pharmaceuticals Inc. | 8 | $166 |
| Novo Nordisk | 5 | $111 |
| Amarin Pharma, Inc. | 5 | $95 |
| Sanofi-aventis U.S. LLC | 5 | $95 |
| Bayer | 4 | $88 |
| Pfizer | 4 | $77 |
| Eisai Inc. | 3 | $57 |
| Abbott | 1 | $49 |
| E.r. Squibb & Sons, L.L.C. | 3 | $48 |
| Amgen | 2 | $42 |
| Ardelyx, Inc. | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| GSK | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Alfasigma USA, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Fresenius Kabi USA, LLC | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CALQUENCE$125
How this compares
$3,522 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 73 | $60,541 |
| JardianceEmpagliflozin | 63 | $55,588 |
| XareltoRivaroxaban | 38 | $29,235 |
| OzempicSemaglutide | 23 | $23,704 |
| MounjaroTirzepatide | 21 | $22,932 |
| TradjentaLinagliptin | 19 | $19,538 |
| GemtesaVibegron | 25 | $18,348 |
| LinzessLinaclotide | 27 | $18,047 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $16,633 |
| EntrestoSacubitril/Valsartan | 11 | $12,033 |
| Spiriva RespimatTiotropium Bromide | 22 | $11,226 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $11,054 |
| MyrbetriqMirabegron | 16 | $9,236 |
| Omeprazole | 307 | $7,997 |
| SynthroidLevothyroxine Sodium | 51 | $5,593 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $497 | $86,352104 claims |
| PfizerEliquis | $77 | $60,54173 claims |
| Johnson & JohnsonXarelto | $238 | $29,23538 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $20 | $27,68748 claims |
| Novo NordiskOzempic | $111 | $23,70423 claims |
| AbbVieLinzess, Synthroid | $595 | $23,64078 claims |
| Lilly USA, LLCMounjaro | $228 | $22,93221 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $411 | $18,34825 claims |
| NovartisEntresto | $304 | $12,03311 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $9,23616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Coral Gables
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Jeffrey RosenCoral Gables$17M
- Carlos IglesiasCoral Gables$6.6M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.